Hematologic Malignancy
Childhood Acute Leukemia
CI-CAN-00002184Explore in graph →
PediatricHematologic77 active trials13 evidence items
- NCIt
- C187056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002184Explore in graph →
Clinical trials
462 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (40)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02220985 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | completed | Phase 2 | 84 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 |
| Apr 15, 2026 |
| clinicaltrials |
| NCT05466994 | A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study) | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT01760655 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | completed | Phase 2 | 62 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT00357565 | Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | completed | Phase 2 | 34 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT04325841 | Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children | completed | Phase 2 | 2 | Beijing Boren HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT01858740 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | completed | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05045443 | Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia(CurcumPedALL) | completed | Phase 2 | 30 | Ain Shams UniversityOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT02642965 | Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 38 | Children's Oncology GroupNETWORK | 2 | Sep 8, 2023 | clinicaltrials |
| NCT04562792 | Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia | completed | Phase 2 | 1 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01700946 | Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | completed | Phase 2 | 80 | St. Jude Children's Research HospitalOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT03455140 | A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)(PARC) | completed | Phase 1 / Phase 2 | 49 | University of BirminghamOTHER | 3 | Sep 2, 2022 | clinicaltrials |
| NCT00061945 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 302 | National Cancer Institute (NCI)NIH | 1 | May 3, 2022 | clinicaltrials |
| NCT00860574 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia | completed | Phase 2 | 96 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT01363128 | Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01445080 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Feb 2, 2021 | clinicaltrials |
| NCT03289455 | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)(AMELIA) | completed | Phase 1 / Phase 2 | 23 | Autolus LimitedINDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT00720109 | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 63 | National Cancer Institute (NCI)NIH | 5 | Apr 13, 2020 | clinicaltrials |
| NCT00040846 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT01527045 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT01251575 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 77 | Fred Hutchinson Cancer CenterOTHER | 2 | Dec 9, 2019 | clinicaltrials |
| NCT00105001 | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Fred Hutchinson Cancer CenterOTHER | 3 | Oct 30, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01175785 | Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | completed | Phase 2 | 15 | Nohla Therapeutics, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT00666588 | Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 3 | May 22, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT00098839 | Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 / Phase 2 | 134 | Children's Oncology GroupNETWORK | 4 | Dec 12, 2017 | clinicaltrials |
| NCT00309907 | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant | completed | Phase 2 | 39 | Children's Oncology GroupNETWORK | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00702403 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00003875 | Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT01083706 | Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00873093 | Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | completed | Phase 2 | 148 | National Cancer Institute (NCI)NIH | 4 | Jan 27, 2017 | clinicaltrials |
| NCT01733953 | Statin Therapy in Young Adult Survivors of Childhood Cancer | completed | Phase 2 | 27 | University of MinnesotaOTHER | 1 | Dec 14, 2016 | clinicaltrials |
| NCT01056614 | Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies | completed | Phase 2 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | May 6, 2016 | clinicaltrials |
| NCT00057811 | Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma | completed | Phase 2 | 97 | Children's Oncology GroupNETWORK | 1 | Sep 19, 2014 | clinicaltrials |
| NCT00002970 | 506U78 in Treating Patients With Refractory Hematologic Cancer | completed | Phase 2 | 148 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00089349 | Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jun 1, 2026source: clinicaltrials